Simpson F O
Wellcome Medical Research Institute, University of Otago Medical School, Dunedin, New Zealand.
J Cardiovasc Pharmacol. 1990;16 Suppl 7:S92-5.
Data from large-scale trials of treatment of mild to moderate hypertension are being misinterpreted and unjustifiably extrapolated to general populations. The main errors include acceptance of "entry" pressures as typical in spite of evidence that true blood pressure was much lower, extrapolation of results in low-risk volunteers to the whole population, neglect of treatment given to the most endangered control subjects, and the assumption that the burden of side effects seen in a rigid high-dose trial is typical of that seen when the same or better drugs are used in clinical practice. The health risks of hypertension and the benefits conferred by antihypertensive therapy are being played down unjustifiably on the basis of inappropriate data.
轻度至中度高血压治疗的大规模试验数据正在被错误解读，并被不合理地外推至普通人群。主要错误包括：尽管有证据表明真实血压要低得多，但仍将“入组”血压视为典型情况；将低风险志愿者的试验结果外推至整个人群；忽视给予最危险对照组受试者的治疗；以及假定在严格的高剂量试验中看到的副作用负担是临床实践中使用相同或更好药物时的典型情况。基于不恰当的数据，高血压的健康风险和抗高血压治疗带来的益处被不合理地淡化了。
